| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 9320143 | European Urology | 2005 | 7 Pages |
Abstract
In conclusion, neridronate is an effective and safe treatment in preventing bone loss in men receiving ADT for prostate cancer.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Carlo Magno, Giuseppina Anastasi, Nunziata Morabito, Agostino Gaudio, Domenica Maisano, Fabio Franchina, Alessandro Galì, Nicola Frisina, Darwin Melloni,